Stock Price Quote

ALKEM LABORATORIES LTD.

NSE : ALKEMBSE : 539523ISIN CODE : INE540L01014Industry : Pharmaceuticals & DrugsHouse : Private
BSE6293.5546.3 (+0.74 %)
PREV CLOSE ( ) 6247.25
OPEN PRICE ( ) 6255.45
BID PRICE (QTY) 6291.60 (1)
OFFER PRICE (QTY) 6301.60 (1)
VOLUME 165
TODAY'S LOW / HIGH ( )6255.45 6293.55
52 WK LOW / HIGH ( )3509.6 6440
NSE6278.7027.25 (+0.44 %)
PREV CLOSE( ) 6251.45
OPEN PRICE ( ) 6267.15
BID PRICE (QTY) 6280.05 (2)
OFFER PRICE (QTY) 6282.10 (4)
VOLUME 6677
TODAY'S LOW / HIGH( ) 6250.05 6298.95
52 WK LOW / HIGH ( )3509.95 6439.9
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 08-08 1973
Management Info
Basudeo N Singh - Chairman Sandeep Singh - Managing Director
Registered Office

Address Alkem House,Senapati Bapat Marg,Lower Parel (West),
Mumbai,
Maharashtra-400013

Phone 022 3982 9999

Email investors@alkem.com / contact@alkem.com

Website www.alkemlabs.com

Registrars Details
Link Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE

NEWS

11Oct Alkem Laboratories rises on signing li
Alkem Laboratories is currently trading at Rs. 6213.50, up by 77.50 poin..
10Oct Alkem Laboratories signs licensing agr
Alkem Laboratories has entered into a licensing agreement with US-based..
19Sep Alkem Laboratories submits analyst mee
With reference to relevant provisions of SEBI (Listing Obligations and D..
17Sep Alkem Laboratories incorporates wholly
Alkem Laboratories has incorporated Wholly Owned Subsidiary (WOS) namely..
17Sep Alkem Laboratories informs about incor
Pursuant to Regulation 30 of the SEBI LODR Regulations, Alkem Laboratori..

Financials

in Millions
QTR Jun 24 ANNUAL 24
Net Profit5832.517471.5
Gross Profit 6409.4 18810.3
Operating Profit 7267.322711.2
Net Sales 2500197477.2

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Abbott India (BSE)
peergroup  29150.00 (1.07%)
M.Cap ( in Cr)61284.58
Pfizer (BSE)
peergroup  5969.80 (2.25%)
M.Cap ( in Cr)26710.73
Neuland Laboratories (BSE)
peergroup  14363.45 (0.73%)
M.Cap ( in Cr)18295.36
RPG Life Sciences (BSE)
peergroup  2778.75 (3.42%)
M.Cap ( in Cr)4443.70
Ajanta Pharma (BSE)
peergroup  3335.60 (2.43%)
M.Cap ( in Cr)40678.25

Shareholding Pattern

PROMOTERS 56.38%
FI/BANKS/INSURANCE 2.85%
NON-INSTITUTION 16.36%
MUTUAL FUNDS/UTI 14.72%
GOVERNMENT 0%
FII 0%

About Alkem Laboratories Ltd.

Alkem Laboratories Ltd. was incorporated in the year 1973. Its today's share price is 6293.55. Its current market capitalisation stands at Rs 74695.24 Cr. In the latest quarter, company has reported Gross Sales of Rs. 102728.2 Cr and Total Income of Rs.100537.1 Cr. The company's management includes Manish Narang, Sujjain Talwar, Sudha Ravi, Sangeeta Singh, Narendra Kumar Aneja, Arun Kumar Purwar, Srinivas Singh, Sarvesh Singh, Madhurima Singh, Mritunjay Kumar Singh, Sandeep Singh, Basudeo N Singh.

It is listed on the BSE with a BSE Code of 539523 , NSE with an NSE Symbol of ALKEM and ISIN of INE540L01014. It's Registered office is at Alkem House,Senapati Bapat Marg,Lower Parel (West)Mumbai-400013, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are BSR & Co LLP, RS Sanghai & Associates

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.